Form 4 for VOR Vor Biopharma Inc.
Accepted 2025-02-05 00:00:00 ET · period of report 2025-02-03 · accession 0001415889-25-003173 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-05 | 2025-02-03 | VOR | Attar Eyal C. | Chief MEDICAL Off | A - Grant | $0.00 | +52.5K | 132.6K | +66% | $0 |
| D | 2025-02-05 | 2025-02-03 | VOR | Attar Eyal C. | Chief MEDICAL Off | F - Tax | $1.34 | -1,353 | 80.1K | -2% | -$1,813 |
| DM | 2025-02-05 | 2025-02-03 | VOR | Attar Eyal C. | Chief MEDICAL Off | A - Grant | $0.00 | +913.0K | 125.0K | New | $0 |
| DM | 2025-02-05 | 2025-02-03 | VOR | Attar Eyal C. | Chief MEDICAL Off | D - Sale to Iss | $0.00 | -598.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-03 | A | A | 52,500 | $0.00 | 132,586 | D | — | — | (F2) Represents the number of shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2025, subject to the Reporting Person's continued service as of each such date. |
| 2 | Common | Common Stock | 2025-02-03 | F | D | 1,353 | $1.34 | 80,086 | D | — | — | (F1) Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). |
| 3 | Derivative | Employee Stock Option (right to buy) | 2025-02-03 | A | A | 109,000 | $0.00 | 109,000 | D | $1.34 · — to 2033-02-05 | 109,000 Common Stock | (F5) The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. (F6) The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2025-02-03 | D | D | 364,000 | $0.00 | 0 | D | $3.77 · — to 2032-10-10 | 364,000 Common Stock | (F4) 1/4th of the shares underlying the option vested on October 11, 2023, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. |
| 5 | Derivative | Employee Stock Option (right to buy) | 2025-02-03 | A | A | 364,000 | $0.00 | 364,000 | D | $1.34 · — to 2032-10-10 | 364,000 Common Stock | (F5) The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. (F4) 1/4th of the shares underlying the option vested on October 11, 2023, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. |
| 6 | Derivative | Employee Stock Option (right to buy) | 2025-02-03 | A | A | 315,000 | $0.00 | 315,000 | D | $1.34 · — to 2035-02-02 | 315,000 Common Stock | (F8) The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2025, in each case subject to the Reporting Person's continued service as of each such date. |
| 7 | Derivative | Employee Stock Option (right to buy) | 2025-02-03 | A | A | 125,000 | $0.00 | 125,000 | D | $1.34 · — to 2034-01-28 | 125,000 Common Stock | (F5) The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. (F7) The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2025-02-03 | D | D | 125,000 | $0.00 | 0 | D | $2.41 · — to 2034-01-28 | 125,000 Common Stock | (F7) The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2025-02-03 | D | D | 109,000 | $0.00 | 0 | D | $5.55 · — to 2033-02-05 | 109,000 Common Stock | (F6) The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. |